Hepatic encephalopathy
Versantis AG focuses on overt hepatic encephalopathy in the setting of acute decompensation of liver cirrhosis and acute-on-chronic liver failure, with interest in the neurological and metabolic consequences of impaired liver function.
- Hyperammonemia
- Acute decompensation of cirrhosis
- Standard of care support in encephalopathy
The research activity in this area centers on restoring clinical stability in patients with impaired mental status linked to advanced liver disease.
Acute-on-chronic liver failure
The sponsor also studies ACLF across grades 1, 2, and 3a, reflecting a therapeutic interest in severe liver dysfunction marked by systemic inflammation, organ failure, and high mortality risk.
- CLIF-C ACLF score
- Hepatic and extrahepatic organ dysfunction
- Advanced cirrhosis
This area includes patients with complex disease burden where liver failure intersects with broader physiological decline.
Ascites and abdominal fluid retention
Versantis AG is involved in research addressing ascites in people with acute episodes on top of chronic liver disease, a condition closely associated with worsening portal hypertension and advanced hepatic impairment.
- Abdominal fluid accumulation
- Decompensated liver disease
- Complications of cirrhosis
The therapeutic interest extends to liver-related fluid management alongside neurological and metabolic complications.
Supportive liver disease care
The sponsor’s clinical research spans treatment settings where standard of care is used in patients with severe hepatic illness, with attention to clinically meaningful improvement in liver-related symptoms and disease burden.
- Advanced hepatic disease
- Metabolic clearance impairment
- Neurological complications of liver failure
These studies reflect a concentrated interest in medical conditions arising from progressive liver dysfunction and its systemic effects.
